Pyxis Oncology Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.16
- Today's High:
- $2.35
- Open Price:
- $2.28
- 52W Low:
- $1.1
- 52W High:
- $6.92
- Prev. Close:
- $2.3
- Volume:
- 129792
Company Statistics
- Market Cap.:
- $101.78 million
- Book Value:
- 3.689
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.37%
- Return on Equity TTM:
- -55.38%
Company Profile
Pyxis Oncology Inc had its IPO on 2021-10-08 under the ticker symbol PYXS.
The company operates in the Healthcare sector and Biotechnology industry. Pyxis Oncology Inc has a staff strength of 72 employees.
Stock update
Shares of Pyxis Oncology Inc opened at $2.28 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.16 - $2.35, and closed at $2.22.
This is a -3.48% slip from the previous day's closing price.
A total volume of 129,792 shares were traded at the close of the day’s session.
In the last one week, shares of Pyxis Oncology Inc have slipped by -4.31%.
Pyxis Oncology Inc's Key Ratios
Pyxis Oncology Inc has a market cap of $101.78 million, indicating a price to book ratio of 0.2176 and a price to sales ratio of 0.
In the last 12-months Pyxis Oncology Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-103733000. The EBITDA ratio measures Pyxis Oncology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pyxis Oncology Inc’s operating margin was 0% while its return on assets stood at -31.37% with a return of equity of -55.38%.
In Q2, Pyxis Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Pyxis Oncology Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pyxis Oncology Inc’s profitability.
Pyxis Oncology Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3966. Its price to sales ratio in the trailing 12-months stood at 0.
Pyxis Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $175.23 million
- Total Liabilities
- $9.23 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $2.26 million
- Dividend Payout Ratio
- 0%
Pyxis Oncology Inc ended 2024 with $175.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $175.23 million while shareholder equity stood at $145.28 million.
Pyxis Oncology Inc ended 2024 with $0 in deferred long-term liabilities, $9.23 million in other current liabilities, 39000.00 in common stock, $-247579000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.90 million and cash and short-term investments were $142.66 million. The company’s total short-term debt was $527,000 while long-term debt stood at $0.
Pyxis Oncology Inc’s total current assets stands at $149.30 million while long-term investments were $0 and short-term investments were $116.77 million. Its net receivables were $0 compared to accounts payable of $1.31 million and inventory worth $0.
In 2024, Pyxis Oncology Inc's operating cash flow was $0 while its capital expenditure stood at $2.26 million.
Comparatively, Pyxis Oncology Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.22
- 52-Week High
- $6.92
- 52-Week Low
- $1.1
- Analyst Target Price
- $10.25
Pyxis Oncology Inc stock is currently trading at $2.22 per share. It touched a 52-week high of $6.92 and a 52-week low of $6.92. Analysts tracking the stock have a 12-month average target price of $10.25.
Its 50-day moving average was $2.42 and 200-day moving average was $2.37 The short ratio stood at 5.77 indicating a short percent outstanding of 0%.
Around 3092.5% of the company’s stock are held by insiders while 2623.6% are held by institutions.
Frequently Asked Questions About Pyxis Oncology Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company’s antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.